title: PPAR-γ agonists, mainly 15d-PGJ(2), reduce eosinophil recruitment following allergen challenge.
abstract: We evaluate the immunomodulation of Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists 15d-PGJ(2) and rosiglitazone (RGZ) in a model of chronic eosinophilia. 15d-PGJ(2) and RGZ significantly reduce eosinophil migration into the peritoneal cavity and down-regulate the eosinopoiesis. The synthesis of IL-5 was decreased after the treatment with 15d-PGJ(2) and RGZ corroborating with the eosinophil migration inhibition. However, IgE was decreased only after the administration of 15d-PGJ(2) in part due to B-cell inhibition. We also observed a decrease in the synthesis of IL-33, IL-17 and IL-23, suggesting that besides the modulation of Th2 pattern, there is a modulation via IL-23 and IL-17 suggesting a role of these cytokines in the eosinophil recruitment. In fact IL-17(-/-) mice failed to develop an eosinophilic response. Altogether, the results showed that PPAR-γ agonists mainly 15d-PGJ(2), have therapeutic efficacy in eosinophil-induced diseases with an alternative mechanism of control, via IL-23/IL-17 and IL-33.
authors.affiliation: Laboratory of Immunology, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil.
authors.forename: Thais S
authors.initials: TS
authors.lastname: Farnesi-de-Assunção
authors.forename: Claudiney F
authors.initials: CF
authors.lastname: Alves
authors.forename: Vanessa
authors.initials: V
authors.lastname: Carregaro
authors.forename: Jhony R
authors.initials: JR
authors.lastname: de Oliveira
authors.forename: Carlos A T
authors.initials: CA
authors.lastname: da Silva
authors.forename: Alessandra B
authors.initials: AB
authors.lastname: Cheraim
authors.forename: Fernando Q
authors.initials: FQ
authors.lastname: Cunha
authors.forename: Marcelo H
authors.initials: MH
authors.lastname: Napimoga
mesh_terms: D000485:Allergens / Q000276:immunology / Q000494:pharmacology*; D000818:Animals; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D049109:Cell Proliferation; D004195:Disease Models, Animal; D004802:Eosinophilia / Q000097:blood / Q000276:immunology / Q000517:prevention & control; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology; D005434:Flow Cytometry; D007073:Immunoglobulin E / Q000097:blood; D007249:Inflammation / Q000097:blood / Q000276:immunology; D007378:Interleukins / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D047495:PPAR gamma / Q000819:agonists* / Q000276:immunology; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: C477819:15-deoxyprostaglandin J2; D000485:Allergens; D007378:Interleukins; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D007073:Immunoglobulin E; D015230:Prostaglandin D2